Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Nov;85(11):1646–1654. doi: 10.1054/bjoc.2001.2150

Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study)

O Oberlin 1, M C Le Deley 2, B N'Guyen Bui 3, J C Gentet 4, T Philip 5, P Terrier 6, C Carrie 7, F Mechinaud 8, C Schmitt 9, A Babin-Boillettot 10, J Michon 11
PMCID: PMC2363978  PMID: 11742482

Abstract

Purpose: (1) To improve survival rates in patients with Ewing's sarcoma (ES) or peripheral neuroectodermal tumours (PNET) using semi-continuous chemotherapy and aiming to peform surgery in all; (2) To identify early prognostic factors to tailor therapy for future studies. Patients and methods One hundred and forty-one patients were entered onto the trial between January 1988 and December 1991. Induction therapy consisted of five courses of Cytoxan, 150 mg/m2 × 7 days, followed by Doxorubicin, 35 mg/m2 i.v on day 8 given at short intervals. Surgery was recommended whenever possible. The delivery of radiation therapy was based on the quality of resection and the histological response to CT. Maintenance chemotherapy consisted of vincristine + actinomycin and cytoxan + doxorubicin. The total duration of therapy was 10 months. Results After a median follow-up of 8.5 years, the projected overall survival at 5 years was 66% and disease-free survival (DFS) was 58%. In patients treated by surgery, only the histological response to CT had an influence on survival: 75% DFS for patients with a good histological response (less than 5% of cells), 48% for intermediate responders and only 20% for poor responders (≥ 30% of cells), P < 0.0001. The initial tumor volume by itself had no influence on DFS in these patients. In contrast, the tumour volume had a strong impact on DFS in patients treated by radiation therapy alone. Age had no impact on outcome. Conclusion Therapeutic trials for localized Ewing's sarcoma should be based on the histological response to chemotherapy or on the tumour volume according to the modality used for local therapy. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: Ewing's tumour, chemotherapy, prognostic factors

Full Text

The Full Text of this article is available as a PDF (91.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arai Y., Kun L. E., Brooks M. T., Fairclough D. L., Fontanesi J., Meyer W. H., Hayes F. A., Thompson E., Rao B. N. Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1501–1508. doi: 10.1016/0360-3016(91)90325-x. [DOI] [PubMed] [Google Scholar]
  2. Bacci G., Ferrari S., Bertoni F., Rimondini S., Longhi A., Bacchini P., Forni C., Manfrini M., Donati D., Picci P. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000 Jan;18(1):4–11. doi: 10.1200/JCO.2000.18.1.4. [DOI] [PubMed] [Google Scholar]
  3. Bacci G., Ferrari S., Comandone A., Zanone A., Ruggieri P., Longhi A., Bertoni F., Forni C., Versari M., Rimondini S. Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Acta Oncol. 2000;39(1):111–116. doi: 10.1080/028418600431076. [DOI] [PubMed] [Google Scholar]
  4. Bacci G., Picci P., Gherlinzoni F., Capanna R., Calderoni P., Putti C., Mancini A., Campanacci M. Localized Ewing's sarcoma of bone: ten years' experience at the Istituto Ortopedico Rizzoli in 124 cases treated with multimodal therapy. Eur J Cancer Clin Oncol. 1985 Feb;21(2):163–173. doi: 10.1016/0277-5379(85)90168-3. [DOI] [PubMed] [Google Scholar]
  5. Barbieri E., Emiliani E., Zini G., Mancini A., Toni A., Frezza G., Neri S., Putti C., Babini L. Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients. Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1165–1170. doi: 10.1016/0360-3016(90)90223-7. [DOI] [PubMed] [Google Scholar]
  6. Craft A. W., Cotterill S. J., Bullimore J. A., Pearson D. Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer. 1997 Jun;33(7):1061–1069. doi: 10.1016/s0959-8049(97)00043-9. [DOI] [PubMed] [Google Scholar]
  7. Donaldson S. S., Torrey M., Link M. P., Glicksman A., Gilula L., Laurie F., Manning J., Neff J., Reinus W., Thompson E. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):125–135. doi: 10.1016/s0360-3016(98)00191-6. [DOI] [PubMed] [Google Scholar]
  8. Glasser D. B., Lane J. M., Huvos A. G., Marcove R. C., Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer. 1992 Feb 1;69(3):698–708. doi: 10.1002/1097-0142(19920201)69:3<698::aid-cncr2820690317>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  9. Göbel V., Jürgens H., Etspüler G., Kemperdick H., Jungblut R. M., Stienen U., Göbel U. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol. 1987;113(2):187–191. doi: 10.1007/BF00391442. [DOI] [PubMed] [Google Scholar]
  10. Hayes F. A., Thompson E. I., Hustu H. O., Kumar M., Coburn T., Webber B. The response of Ewing's sarcoma to sequential cyclophosphamide and adriamycin induction therapy. J Clin Oncol. 1983 Jan;1(1):45–51. doi: 10.1200/JCO.1983.1.1.45. [DOI] [PubMed] [Google Scholar]
  11. Hayes F. A., Thompson E. I., Meyer W. H., Kun L., Parham D., Rao B., Kumar M., Hancock M., Parvey L., Magill L. Therapy for localized Ewing's sarcoma of bone. J Clin Oncol. 1989 Feb;7(2):208–213. doi: 10.1200/JCO.1989.7.2.208. [DOI] [PubMed] [Google Scholar]
  12. Hense H. W., Ahrens S., Paulussen M., Lehnert M., Jürgens H. Factors associated with tumor volume and primary metastases in Ewing tumors: results from the (EI)CESS studies. Ann Oncol. 1999 Sep;10(9):1073–1077. doi: 10.1023/a:1008357018737. [DOI] [PubMed] [Google Scholar]
  13. Huvos A. G., Rosen G., Marcove R. C. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977 Jan;101(1):14–18. [PubMed] [Google Scholar]
  14. Jürgens H., Exner U., Gadner H., Harms D., Michaelis J., Sauer R., Treuner J., Voûte T., Winkelmann W., Winkler K. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer. 1988 Jan 1;61(1):23–32. doi: 10.1002/1097-0142(19880101)61:1<23::aid-cncr2820610106>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  15. Kinsella T. J., Miser J. S., Waller B., Venzon D., Glatstein E., Weaver-McClure L., Horowitz M. E. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):389–395. doi: 10.1016/0360-3016(91)90047-8. [DOI] [PubMed] [Google Scholar]
  16. Mendenhall C. M., Marcus R. B., Jr, Enneking W. F., Springfield D. S., Thar T. L., Million R. R. The prognostic significance of soft tissue extension in Ewing's sarcoma. Cancer. 1983 Mar 1;51(5):913–917. doi: 10.1002/1097-0142(19830301)51:5<913::aid-cncr2820510525>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  17. Nesbit M. E., Jr, Gehan E. A., Burgert E. O., Jr, Vietti T. J., Cangir A., Tefft M., Evans R., Thomas P., Askin F. B., Kissane J. M. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol. 1990 Oct;8(10):1664–1674. doi: 10.1200/JCO.1990.8.10.1664. [DOI] [PubMed] [Google Scholar]
  18. Oberlin O., Habrand J. L., Zucker J. M., Brunat-Mentigny M., Terrier-Lacombe M. J., Dubousset J., Gentet J. C., Schmitt C., Ponvert D., Carrié C. No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol. 1992 Sep;10(9):1407–1412. doi: 10.1200/JCO.1992.10.9.1407. [DOI] [PubMed] [Google Scholar]
  19. Oberlin O., Patte C., Demeocq F., Lacombe M. J., Brunat-Mentigny M., Demaille M. C., Tron P., N'Guyen Bui B., Lemerle J. The response to initial chemotherapy as a prognostic factor in localized Ewing's sarcoma. Eur J Cancer Clin Oncol. 1985 Apr;21(4):463–467. doi: 10.1016/0277-5379(85)90038-0. [DOI] [PubMed] [Google Scholar]
  20. Parham D. M., Hijazi Y., Steinberg S. M., Meyer W. H., Horowitz M., Tzen C. Y., Wexler L. H., Tsokos M. Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior. Hum Pathol. 1999 Aug;30(8):911–918. doi: 10.1016/s0046-8177(99)90244-7. [DOI] [PubMed] [Google Scholar]
  21. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Picci P., Rougraff B. T., Bacci G., Neff J. R., Sangiorgi L., Cazzola A., Baldini N., Ferrari S., Mercuri M., Ruggieri P. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol. 1993 Sep;11(9):1763–1769. doi: 10.1200/JCO.1993.11.9.1763. [DOI] [PubMed] [Google Scholar]
  23. Sauer R., Jürgens H., Burgers J. M., Dunst J., Hawlicek R., Michaelis J. Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Radiother Oncol. 1987 Oct;10(2):101–110. doi: 10.1016/s0167-8140(87)80052-x. [DOI] [PubMed] [Google Scholar]
  24. Terrier P., Henry-Amar M., Triche T. J., Horowitz M. E., Terrier-Lacombe M. J., Miser J. S., Kinsella T. J., Contesso G., Llombart-Bosch A. Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis? Eur J Cancer. 1995;31A(3):307–314. doi: 10.1016/0959-8049(94)00417-4. [DOI] [PubMed] [Google Scholar]
  25. Wilkins R. M., Pritchard D. J., Burgert E. O., Jr, Unni K. K. Ewing's sarcoma of bone. Experience with 140 patients. Cancer. 1986 Dec 1;58(11):2551–2555. doi: 10.1002/1097-0142(19861201)58:11<2551::aid-cncr2820581132>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES